Here are the S-3 shelf registrations from Bone Biologics Corp (BBLG) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow BBLG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBLG filings page.
Bone Biologics Corporation is registering up to 6,464,792 shares of common stock for resale by existing security holders. All of these shares are issuable upon exercise of outstanding warrants, including 6,338,031 shares tied to a July 9, 2026 private placement and 126,761 placement agent warrant shares. The company will not receive proceeds from any resale of shares by the selling stockholders, but could receive approximately $6.2 million in gross proceeds if all warrants are exercised for cash, at exercise prices ranging from $0.001 to $1.775 per share. Shares outstanding were 1,810,380 as of July 16, 2026; assuming full cash exercise of the registered warrants, shares outstanding would rise to 8,275,172. The company is a clinical-stage medical device developer focused on NELL-1/DBM bone-regeneration products for spinal fusion and other orthopedic uses and currently carries an auditor “going concern” explanatory paragraph, reflecting the need for additional capital to fund operations and clinical trials.